{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:27:34Z","timestamp":1783445254576,"version":"3.54.6"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Pathologie"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.annpat.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T09:38:08Z","timestamp":1742290688000},"page":"312-320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Les l\u00e9sions apocrines du sein"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3483-9758","authenticated-orcid":false,"given":"Ga\u00ebtan","family":"MacGrogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annpat.2025.03.001_bib0305","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1023\/A:1022896515287","article-title":"The mammary gland and its origin during synapsid evolution","volume":"7","author":"Oftedal","year":"2002","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"10.1016\/j.annpat.2025.03.001_bib0310","series-title":"Breast tumours","article-title":"WHO classification of tumors Editorial Board","year":"2019"},{"key":"10.1016\/j.annpat.2025.03.001_bib0315","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0344-0338(97)80053-2","article-title":"Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ","volume":"193","author":"Gatalica","year":"1997","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.annpat.2025.03.001_bib0320","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/jcp.52.11.838","article-title":"Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors","volume":"52","author":"Selim","year":"1999","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0325","series-title":"Breast carcinoma risk and detection","article-title":"multiple intaductal papilloma","author":"Haagensen","year":"1981"},{"key":"10.1016\/j.annpat.2025.03.001_bib0330","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0046-8177(87)80169-7","article-title":"Apocrine cystic metaplasia: subgross pathology and prevalence in cancer-associated versus random autopsy breasts","volume":"18","author":"Wellings","year":"1987","journal-title":"Hum Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0335","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1074\/mcp.M500348-MCP200","article-title":"Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype","volume":"5","author":"Celis","year":"2006","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.annpat.2025.03.001_bib0340","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/1097-0142(197103)27:3<643::AID-CNCR2820270320>3.0.CO;2-9","article-title":"DNA content in \u201capocrine metaplasia\u201d of fibrocystic disease of the breast","volume":"27","author":"Izuo","year":"1971","journal-title":"Cancer"},{"key":"10.1016\/j.annpat.2025.03.001_bib0345","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/PAS.0b013e31820598a2","article-title":"Diminished number or complete loss of myoepithelial cells associated with metaplastic and neoplastic apocrine lesions of the breast","volume":"35","author":"Tramm","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0350","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1600-0463.2011.02840.x","article-title":"Benign apocrine papillary lesions of the breast lacking or virtually lacking myoepithelial cells-potential pitfalls in diagnosing malignancy","volume":"120","author":"Cserni","year":"2012","journal-title":"APMIS"},{"key":"10.1016\/j.annpat.2025.03.001_bib0355","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/00000478-199106000-00007","article-title":"Calcium oxalate crystals in the breast. Pathology and significance","volume":"15","author":"Gonzalez","year":"1991","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0360","series-title":"Pathology of the breast","author":"Tavassoli","year":"1992"},{"key":"10.1016\/j.annpat.2025.03.001_bib0365","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/jum.15240","article-title":"Ultrasound features and rate of upgrade to malignancy in atypical apocrine lesions of the breast","volume":"39","author":"Jung","year":"2020","journal-title":"J Ultrasound Med"},{"key":"10.1016\/j.annpat.2025.03.001_bib0370","doi-asserted-by":"crossref","first-page":"100125","DOI":"10.1016\/j.modpat.2023.100125","article-title":"Triple-negative apocrine carcinomas: toward a unified group with shared molecular features and clinical behavior","volume":"36","author":"Schwartz","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0375","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/hupa.2001.24327","article-title":"Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers","volume":"32","author":"Leal","year":"2001","journal-title":"Hum Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0380","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/0046-8177(92)90321-S","article-title":"Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation","volume":"23","author":"Eusebi","year":"1992","journal-title":"Hum Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0385","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/PAS.0b013e3181b18a89","article-title":"Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast","volume":"33","author":"Chen","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0390","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/PAS.0000000000001493","article-title":"Apocrine variant of pleomorphic lobular carcinoma in situ: further clinical, histopathologic, immunohistochemical, and molecular characterization of an emerging entity","volume":"44","author":"Zhong","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0395","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41379-021-00796-9","article-title":"Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision","volume":"34","author":"Kuba","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0400","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/PAS.0000000000001191","article-title":"Pleomorphic and florid lobular carcinoma in situ variants of the breast: a clinicopathologic study of 85\u00a0cases with and without invasive carcinoma from a single academic center","volume":"43","author":"Shamir","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0405","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/jso.26129","article-title":"Triple-negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple-negative breast cancers","volume":"122","author":"Arciero","year":"2020","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0410","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10549-022-06578-4","article-title":"HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome","volume":"193","author":"Skenderi","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annpat.2025.03.001_bib0415","doi-asserted-by":"crossref","first-page":"24579","DOI":"10.18632\/oncotarget.15597","article-title":"Dose invasive apocrine adenocarcinoma has worse prognosis than invasive ductal carcinoma of breast: evidence from SEER database","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.annpat.2025.03.001_bib0420","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/PAS.0000000000000671","article-title":"Pure apocrine carcinomas represent a clinicopathologically distinct androgen receptor-positive subset of triple-negative breast cancers","volume":"40","author":"Mills","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0425","first-page":"336","article-title":"Recommendations for the immunohistochemistry of the hormonal receptors on paraffin sections in breast cancer. Update 1999","volume":"19","year":"1999","journal-title":"Ann Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0430","first-page":"545","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"144","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0435","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.breast.2004.06.003","article-title":"\u2018Pure\u2019 invasive apocrine carcinoma of the breast: a new clinicopathological entity?","volume":"14","author":"Japaze","year":"2005","journal-title":"Breast"},{"key":"10.1016\/j.annpat.2025.03.001_bib0440","first-page":"1393","article-title":"Apocrine carcinoma of the breast: a comprehensive review","volume":"28","author":"Vranic","year":"2013","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0445","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1038\/emboj.2011.216","article-title":"Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1","volume":"30","author":"Robinson","year":"2011","journal-title":"EMBO J"},{"key":"10.1016\/j.annpat.2025.03.001_bib0450","doi-asserted-by":"crossref","first-page":"994","DOI":"10.5858\/arpa.2021-0039-OA","article-title":"FOXC1","volume":"146","author":"Li","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.annpat.2025.03.001_bib0455","doi-asserted-by":"crossref","first-page":"200","DOI":"10.5858\/arpa.2022-0289-OA","article-title":"TRPS1\u00a0and GATA3\u00a0expression in invasive breast carcinoma with apocrine differentiation","volume":"148","author":"Wang","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.annpat.2025.03.001_bib0460","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.humpath.2021.07.005","article-title":"\u03b1-Methylacyl-CoA racemase: a useful immunohistochemical marker of breast carcinoma with apocrine differentiation","volume":"116","author":"Nakamura","year":"2021","journal-title":"Hum Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0465","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/modpathol.2010.50","article-title":"EGFR and HER-2\/neu expression in invasive apocrine carcinoma of the breast","volume":"23","author":"Vranic","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0470","doi-asserted-by":"crossref","first-page":"256","DOI":"10.17305\/bb.2023.9868","article-title":"The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2\u00a0status","volume":"24","author":"Gatalica","year":"2024","journal-title":"Biomol Biomed"},{"key":"10.1016\/j.annpat.2025.03.001_bib0475","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41379-020-0589-x","article-title":"Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18\u00a0pure triple-negative apocrine carcinomas","volume":"33","author":"Sun","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0480","doi-asserted-by":"crossref","first-page":"151901","DOI":"10.1016\/j.anndiagpath.2022.151901","article-title":"Histological subtype is associated with PD-L1\u00a0expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma","volume":"57","author":"Salisbury","year":"2022","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0485","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/modpathol.2016.39","article-title":"Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology","volume":"29","author":"Weisman","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0490","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/bcr2626","article-title":"Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations","volume":"12","author":"Banneau","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.annpat.2025.03.001_bib0495","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1038\/sj.onc.1208561","article-title":"Identification of molecular apocrine breast tumours by microarray analysis","volume":"24","author":"Farmer","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.annpat.2025.03.001_bib0500","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.annpat.2025.03.001_bib0505","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0510","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/onc.2011.301","article-title":"A refined molecular taxonomy of breast cancer","volume":"31","author":"Guedj","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.annpat.2025.03.001_bib0515","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.annpat.2025.03.001_bib0520","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annpat.2025.03.001_bib0525","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annpat.2025.03.001_bib0530","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s41379-021-00742-9","article-title":"Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations","volume":"34","author":"Bergeron","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0535","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41416-019-0420-y","article-title":"Molecular apocrine tumours in EORTC 10994\/BIG 1-00\u00a0phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes","volume":"120","author":"Bonnefoi","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annpat.2025.03.001_bib0540","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1158\/0008-5472.CAN-23-4066","article-title":"Molecular characterization and classification of HER2-positive breast cancer inform tailored therapeutic strategies","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.annpat.2025.03.001_bib0545","doi-asserted-by":"crossref","first-page":"12222","DOI":"10.1038\/ncomms12222","article-title":"A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers","volume":"7","author":"Ferrari","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.annpat.2025.03.001_bib0550","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13058-018-0933-y","article-title":"HER2\u00a0is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors","volume":"20","author":"Daemen","year":"2018","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.annpat.2025.03.001_bib0555","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/annonc\/mdy024","article-title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","volume":"29","author":"Bareche","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0560","doi-asserted-by":"crossref","first-page":"26406","DOI":"10.18632\/oncotarget.25413","article-title":"Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy","volume":"9","author":"Santonja","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.annpat.2025.03.001_bib0565","doi-asserted-by":"crossref","first-page":"zcac018","DOI":"10.1093\/narcan\/zcac018","article-title":"Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response","volume":"4","author":"Thompson","year":"2022","journal-title":"NAR Cancer"},{"key":"10.1016\/j.annpat.2025.03.001_bib0570","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/1078-0432.CCR-22-2191","article-title":"Triple-negative PAM50\u00a0non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine","volume":"29","author":"Asleh","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annpat.2025.03.001_bib0575","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/bjc.2015.464","article-title":"Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-\u03b1-negative breast cancer","volume":"114","author":"Hilborn","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annpat.2025.03.001_bib0580","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdw067","article-title":"A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)","volume":"27","author":"Bonnefoi","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0585","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1158\/1078-0432.CCR-12-3327","article-title":"Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer","volume":"19","author":"Gucalp","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annpat.2025.03.001_bib0590","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2025.03.001_bib0595","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-19-2170","article-title":"TBCRC 032\u00a0IB\/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR(+) metastatic triple-negative breast cancer","volume":"26","author":"Lehmann","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annpat.2025.03.001_bib0300","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1158\/1078-0432.CCR-18-1469","article-title":"Enhancing abiraterone acetate efficacy in androgen receptor-positive triple-negative breast cancer: Chk1\u00a0as a potential target","volume":"25","author":"Grellety","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Annales de Pathologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0242649825000318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0242649825000318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:02:14Z","timestamp":1783443734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0242649825000318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0242649825000318"],"URL":"https:\/\/doi.org\/10.1016\/j.annpat.2025.03.001","relation":{},"ISSN":["0242-6498"],"issn-type":[{"value":"0242-6498","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les l\u00e9sions apocrines du sein","name":"articletitle","label":"Article Title"},{"value":"Annales de Pathologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annpat.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}